~~**What is claimed is:**~~

Claims

1. An aqueous pharmaceutical composition comprising ~~at least 50~~between about 60 mg/ml ~~to~~and about 120 mg/ml of an anti-VEGF antibody comprising the sequences of SEQ ID NO: 1 and SEQ ID NO: 2, about 4.5% to 11% (w/v) sucrose, 5-20 mM sodium citrate, and 0.~~001% to 0.05~~02% polysorbate 80 (w/v), wherein the pH of the composition is ~~about 7.0 to about 7.6.~~7.2±1%.

2. The aqueous pharmaceutical composition according to claim 1, wherein the anti-VEGF antibody comprises the sequence of SEQ ID NO: 3 or 4.

3. The aqueous pharmaceutical composition according to claim 1 or 2, wherein the anti-VEGF antibody comprises the sequence of SEQ ID NO: 3 and 4.

4. The aqueous pharmaceutical composition of any one of ~~the preceding~~ claims 1 to 3, wherein the pH of the composition is ~~about 6.8~~7.2.

~~5. The aqueous pharmaceutical composition of any one of the preceding claims, wherein the pH of the composition is about 7.2.~~

1 to 4

~~6. The aqueous pharmaceutical composition of any of the preceding claims, comprising 0.004% polysorbate 80 (w/v).~~

~~7. The aqueous pharmaceutical composition of any of the preceding claims, comprising 0.02% polysorbate 80 (w/v).~~

~~8.~~5. ~~The aqueous pharmaceutical composition of any of the preceding claims~~, comprising between about 60 mg/ml and about 120 mg/ml of an anti-VEGF antibody.

~~9.~~6. The aqueous pharmaceutical composition of any one of claims 1 to ~~7~~4, comprising about 20 mg/ml of an anti-VEGF antibody.

~~10.~~7. The aqueous pharmaceutical composition of any one of ~~the preceding~~ claims 1 to 6, comprising 5.5% to 7.0% (w/v) sucrose.

~~11.~~8. The aqueous pharmaceutical composition of claim 1, comprising 6.5% (w/v) sucrose, 12 mM sodium citrate, 0.02% (w/v) polysorbate 80, and wherein the pH is ~~about~~ 7.2~~.~~±1%.

9. The aqueous pharmaceutical composition of claim 8, comprising about 60 mg/ml of an anti-VEGF antibody.

~~12.~~10. The aqueous pharmaceutical composition of ~~11~~claim 8, comprising 3 mg of an anti-VEGF antibody.

~~13.~~11. The aqueous pharmaceutical composition of any of claim 1, comprising 5.8% (w/v) sucrose, 10 mM sodium citrate, 0.02% (w/v) polysorbate 80, and wherein the pH is ~~about~~ 7.2~~.~~±1%.

12. The aqueous pharmaceutical composition of claim 11, comprising about 120 mg/ml of an anti-VEGF antibody.

~~14.~~13. The aqueous pharmaceutical composition of ~~13~~claim 11, comprising 6 mg of an anti-VEGF antibody.

14. An aqueous pharmaceutical composition comprising 60 mg/ml of an anti-VEGF antibody comprising the sequences of SEQ ID NO: 3 or SEQ ID NO: 4, 6.5% (w/v) sucrose, 12 mM sodium citrate, and 0.02% (w/v) polysorbate 80, and wherein the pH is 7.2±1%.

15. An aqueous pharmaceutical composition comprising 120 mg/ml of an anti-VEGF antibody comprising the sequences of SEQ ID NO: 3 or SEQ ID NO: 4,

comprising 5.8% (w/v) sucrose, 10 mM sodium citrate, and 0.02% (w/v) polysorbate 80, and wherein the pH is 7.2±1%.

~~15.~~16. The aqueous pharmaceutical composition of any one of ~~the preceding~~ claims 1 to 15, wherein said composition is stable for at least 18 months at 2-8°C.

~~16.~~17. The aqueous pharmaceutical composition of any one of ~~the preceding~~ claims 1 to 16, wherein said composition is liquid.

18. ~~A method for delivering an anti-VEGF antibody~~An aqueous pharmaceutical composition of any one of claims 1 to 17 for use in delivering an anti-VEGF antibody to a subject~~, comprising administering to said subject~~.

~~17.~~ Use of the aqueous pharmaceutical composition of any one of claims 1 to 17 in the ~~preceding claims.~~

~~18.~~19. ~~A method of treating~~manufacture of a medicament for the treatment of an ocular disease or disorder that is mediated by VEGF~~, comprising administering to a subject the aqueous pharmaceutical composition of any of the preceding claims.~~.

~~19.~~20. The ~~method of~~use according to claim ~~18~~19, wherein said ocular disease or disorder is an ocular neovascular disease.

~~20.~~21. The ~~method of any of~~ use according to claims ~~17~~-19 or 20, wherein the aqueous pharmaceutical composition is to be administered to a subject, and wherein said administration is intravitreal.

~~21. An aqueous pharmaceutical composition of any one of the preceding claims for use in delivering an anti-VEGF antibody to a subject, comprising a step of administering the aqueous pharmaceutical composition to the subject.~~

~~22. An aqueous pharmaceutical composition of any one of the preceding claims for use in treating an ocular disease or disorder that is mediated by VEGF, comprising administering the aqueous pharmaceutical composition to a subject.~~

~~23. An aqueous pharmaceutical composition for use according to claim 22, wherein said ocular disease or disorder is an ocular neovascular disease.~~

~~24. An aqueous pharmaceutical composition for use according to any of claims 21-23, wherein said administration is intravitreal.~~

~~25. A dosage form comprising the aqueous pharmaceutical composition of any one of claims 1-16 or 21-24.~~

~~26.~~22. A delivery device comprising the aqueous pharmaceutical composition of any one of claims 1~~-16 or 21-24~~ to 17.

~~27.~~ The delivery device of claim ~~26~~22, which is a pre-filled syringe.

~~28.~~23.